Advances in the integration of drug metabolism into the lead optimization paradigm.
The lead optimization paradigm includes a team of experts that has a multitude of parameters to consider when moving from an initial lead compound through the lead optimization phase to the development phase. While in the past the team may have had only a medicinal chemist and a pharmacologist, the current team would often include experts in the areas of drug metabolism and pharmacokinetics (DMPK) as well as chemical toxicity. This review provides an overview of the some of the recent advances in the areas of DMPK screening plus a discussion of some of the assays that can be used to begin to screen for toxicity issues. The focus of this review is the major potential problem areas: oral bioavailability, half-life, drug-drug interactions and metabolism and toxicity issues.
Korfmacher
Walter A
WA
Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. walter.korfmacher@spcorp.com
D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006207:Half-Life; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage / Q000378:metabolism*; D010599:Pharmacokinetics
D004364:Pharmaceutical Preparations